19th May 2014 10:45
LONDON (Alliance News) - NetScientific PLC said Monday its Palo Alto-based subsidiary, Vortex Biosciences Inc, has signed a research agreement with the Rowland Institute at Harvard University.
The biomedical and healthcare technology investment group said that under the research agreement, the Rowland Institute will explore the use of circulating tumour cell technology in a study to analyse improvements in patient diagnosis and prognosis that may be possible from capturing live CTCs in blood samples.
NetScientific said it believes that, if successful and once the processes are fully developed, they could transform the way medical practitioners select drug treatments for patients and how new classes of anticancer therapeutics are developed.
The Vortex technology enables direct selection and capture of live CTCs from whole blood. Cells can be captured and held within the Vortex microfluidic chip for enumeration and analysis, with work at the Rowland Institute to focus on effecting and evaluating potential drug treatment of live CTCs within the Vortex chip, said NetScientific.
Shares in NetScientific were trading 0.85% higher at 119.00 pence per share Monday morning.
By Alice Attwood; [email protected]; @AliceAtAlliance
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Netscientific